Cyclic GMP‐dependent vasodilatory properties of LASSBio 294 in rat aorta

[1]  S. Salomone,et al.  Facilitation of the vasorelaxant action of calcium antagonists by basal nitric oxide in depolarized artery , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  M. O. Islam,et al.  Stimulation of plasma membrane Ca2+-pump ATPase of vascular smooth muscle by cGMP-dependent protein kinase: Functional reconstitution with purified proteins , 2004, Molecular and Cellular Biochemistry.

[3]  E. Barreiro,et al.  Design and synthesis of novel potent antinociceptive agents: methyl-imidazolyl N-acylhydrazone derivatives. , 2000, Bioorganic & medicinal chemistry.

[4]  J. Beavo,et al.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. , 2000, Current opinion in cell biology.

[5]  H. Kwan,et al.  Store-operated Calcium Entry in Vascular Endothelial Cells Is Inhibited by cGMP via a Protein Kinase G-dependent Mechanism* , 2000, The Journal of Biological Chemistry.

[6]  S. Bolz,et al.  Endothelium‐derived hyperpolarizing factor but not NO reduces smooth muscle Ca2+ during acetylcholine‐induced dilation of microvessels , 1999, British journal of pharmacology.

[7]  H. Kawata,et al.  Biphasic nature of inotropic action of nitric oxide donor NOC7 in guinea-pig ventricular trabeculae. , 1999, The Japanese journal of physiology.

[8]  F. Lezoualc’h,et al.  Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L‐type Ca2+ current in rat ventricular myocytes , 1999, British journal of pharmacology.

[9]  G. Kojda,et al.  Regulation of basal myocardial function by NO. , 1999, Cardiovascular research.

[10]  P. Klatt,et al.  Structure and function of cGMP-dependent protein kinases. , 1999, Reviews of physiology, biochemistry and pharmacology.

[11]  V. Calderone,et al.  Influence of depolarization on vasorelaxant potency and efficacy of Ca2+ entry blockers, K+ channel openers, nitrate derivatives, salbutamol and papaverine in rat aortic rings , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[12]  A. Hobbs.  Soluble guanylate cyclase: the forgotten sibling. , 1997, Trends in pharmacological sciences.

[13]  T. Lincoln,et al.  Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP. , 1997, The Journal of clinical investigation.

[14]  G. Kojda,et al.  Inhibition of nitric oxide synthase and soluble guanylate cyclase induces cardiodepressive effects in normal rat hearts. , 1997, European journal of pharmacology.

[15]  U. Walter,et al.  Distinct and specific functions of cGMP-dependent protein kinases. , 1997, Trends in biochemical sciences.

[16]  H. Coste,et al.  Effects of cyclic GMP elevation on isoprenaline‐induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3 , 1996, British journal of pharmacology.

[17]  E. Delpy,et al.  Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization , 1996, British journal of pharmacology.

[18]  T. Cocks.  Endothelium-dependent vasodilator mechanisms , 1996 .

[19]  J. Polson,et al.  Cyclic nucleotide phosphodiesterases and vascular smooth muscle. , 1996, Annual review of pharmacology and toxicology.

[20]  J. Beavo,et al.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. , 1995, Physiological reviews.

[21]  R. Cohen,et al.  Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle , 1994, Nature.

[22]  R. Cohen,et al.  Potassium channel-mediated relaxation to acetylcholine in rabbit arteries. , 1993, The Journal of pharmacology and experimental therapeutics.

[23]  P. Janssen,et al.  Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. , 1992, The Journal of pharmacology and experimental therapeutics.

[24]  M. Shahid,et al.  Species‐dependent differences in the properties of particulate cyclic nucleotide phosphodiesterase from rat and rabbit ventricular myocardium , 1990, The Journal of pharmacy and pharmacology.

[25]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.